Market Challenges And Opportunities

Market Dynamics

Rising incidence HIV is expected to augment growth of the Burkitt lymphoma treatment market, as Burkitt lymphoma is an AIDS-defining cancer that is expected to occur more frequently in people suffering from HIV than in the general population. According to the Burkitt Lymphoma Society, the condition accounts for an around 40% of all childhood non Hodgkin lymphoma patients worldwide. It also accounts for as many as 40% of all non-Hodgkin lymphomas in HIV/AIDS patients. Also, according to the Cancer Therapy Advisor, Burkitt lymphoma (BL) is the most common pediatric cancer with the disease incidence being 2-3 times higher in sub-Saharan Africa, with an estimated incidence of 3–6 cases per 100,000 children per year. The disease is termed as endemic Burkitt lymphoma, where a majority of cases are related to Epstein-Barr virus (EBV).

Moreover, various government and non-government organizations are undertaking research initiatives to launch efficient treatments and create awareness about the rare disease. For instance, the National Cancer Institute initiated the Burkitt Lymphoma Genome Sequencing Project (BLGSP) to explore potential genetic changes in patients suffering from Burkitt lymphoma (BL) that could lead to better prevention, detection, and treatment of this rare and aggressive cancer. Moreover, researchers at Forgarty International Center and National Cancer Institute are working together to address global health needs related to various cancer types, including Burkitt lymphoma. Non-profit organization such as Burkitt Lymphoma Society supports and connects patients and caregivers by connecting the patients who have received efficient care for Burkitt lymphoma, thus providing information and creating awareness about the rare medical condition. Also, in 2017, the Lymphoma Research Foundation granted US$ 700,000 to funding innovative research that serves education programs, outreach initiatives, and patient services, thus accelerating the burkitt lymphoma treatment market growth.

The presence of potential therapies for the prevention of Burkitt lymphoma is expected to augment the market growth over the forecast period. For instance, Viracta Therapeutics, Inc., initiated Phase 1 b/2 trial for Tractinostat in combination with Valganciclovir indicated for Epstein-Barr virus-positive (EBV+) lymphomas. According to the Cancer Research UK, 2015, around 200,000 new cases and over 140,000 deaths are estimated to be recorded each year due to EBV-associated cancers. Also, the National Cancer Institute initiated Phase 1 clinical trials for antibody therapy, directed against CD19- blinatumomab, a recombinant bispecific antibody in combination with Lenalidomide with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Moreover, the FDA approved a radioimmunotherapy named Zevalin (Ibritumomab tiuxetan) in combination with a radioactive substance linked to a monoclonal antibody named rituximab, to treat patients suffering from certain types of non-Hodgkin lymphoma, including Burkitt lymphoma.